SCHEMBL2815084

SCHEMBL2815084

COc1cccc(-c2cn3c(n2)c(Cl)nc2ccccc23)c1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 4/20 0.58
▸ ADORA1 P30542 1/20 0.42
▸ TLR8 Q9NR97 1/20 0.41
▸ KDM4E B2RXH2 5/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ PDE2A O00408 1/20 0.40
▸ PDE10A Q9Y233 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ HTT P42858 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ PARP1 P09874 1/20 0.40
▸ DPP4 P27487 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2817230 0.90 ADORA2A (0.70) ADORA2AADORA1KDM4ENPC1RAB9A
SCHEMBL2817763 0.87 ADORA2A (0.59) ADORA2AADORA1TLR8KDM4ENPC1
SCHEMBL2816304 0.86 ADORA2A (0.74) ADORA2AADORA1TLR8KDM4ENPC1
SCHEMBL2820066 0.84 ADORA2A (0.56) ADORA2AADORA1TLR8KDM4ENPC1
SCHEMBL2815680 0.81 ADORA2A (0.54) ADORA2AADORA1KDM4ENPC1RAB9A
SCHEMBL2816026 0.79 ADORA2A (0.53) ADORA2AADORA1TLR8KDM4ENPC1
SCHEMBL2818350 0.77 ADORA2A (0.45) ADORA2AADORA1KDM4EALDH1A1MAPT
SCHEMBL2817242 0.77 ADORA2A (0.71) ADORA2AADORA1KDM4ENPC1RAB9A
SCHEMBL2818432 0.76 PDE2A (0.45) ADORA2AKDM4ENPC1RAB9APDE2A
SCHEMBL2816023 0.76 ADORA2A (0.90) ADORA2AADORA1PDE2APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 — — US claimed
EP-2205602-B1 IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS UNIV MONTPELLIER (FR) 2018-09-26 — — EP disclosed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 — — US disclosed
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS IDH3A, NRAS, KRAS ADORA2A 1818/4885ADORA1 1985/4885TLR8 4177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback